BODIHEALTH SYSTEM

K052836 · Usa Laser Therapeutics, Inc. · GZJ · Feb 13, 2007 · Neurology

Device Facts

Record IDK052836
Device NameBODIHEALTH SYSTEM
ApplicantUsa Laser Therapeutics, Inc.
Product CodeGZJ · Neurology
Decision DateFeb 13, 2007
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 882.5890
Device ClassClass 2
AttributesTherapeutic

Intended Use

The BodiHealth System is intended for temporary symptomatic relief and management of chronic intractable pain and as an adjunctive treatment in the management of post-surgical and post-traumatic pain.

Device Story

BodiHealth System is a transcutaneous electrical nerve stimulator (TENS) for pain management. Device delivers electrical impulses to patient via electrodes to provide symptomatic relief of chronic intractable pain and adjunctive treatment for post-surgical/post-traumatic pain. Operated by healthcare providers or patients in clinical or home settings. Output consists of controlled electrical stimulation parameters. Clinical benefit derived from non-invasive pain modulation.

Clinical Evidence

Bench testing only; no clinical data provided.

Technological Characteristics

Transcutaneous electrical nerve stimulator (TENS). Class II device (21 CFR 882.5890). Electrical stimulation output. Form factor and materials not specified.

Indications for Use

Indicated for temporary relief and management of chronic intractable pain, and adjunctive treatment for post-surgical and post-traumatic pain in patients requiring pain management.

Regulatory Classification

Identification

A transcutaneous electrical nerve stimulator for pain relief is a device used to apply an electrical current to electrodes on a patient's skin to treat pain.

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ ## DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/0/Picture/1 description: The image is a black and white circular logo for the U.S. Department of Health and Human Services. The logo features the department's emblem, which is a stylized depiction of an eagle with three bars extending from its wing. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged around the upper portion of the circle. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 USA Laser Therapeutics, Inc. c/o M. Joyce Heinrich Texas Applied Biomedical Services 12101 Cullen Boulevard, #A Houston, Texas 77047 FEB 1 3 2007 Re: K052836 Trade/Device Name: BodiHealth System Regulation Number: 21 CFR 882.5890 Regulation Name: Transcutaneous Electrical Nerve Stimulator for Pain Relief Regulatory Class: Class II Product Code: GZJ Dated: November 14, 2006 Received: November 16, 2006 Dear Ms Heinrich: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {1}------------------------------------------------ Page 2 - M. Joyce Heinrich This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120 Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ BodiHealth System 510(k) Notification October 7, 2005 ## APPENDIX A ## Indications for Use 510(k) Number (if known): Pending Device Name: ר BodiHealth System ## Indications for Use: The BodiHealth System is intended for temporary symptomatic relief and management of chronic intractable pain and as an adjunctive treatment in the management of post-surgical and post-traumatic pain. Prescription Use: X (Part 21 CFR 801 Subpart D) AND/OR Over the Counter Use: (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODpE) ![image](https://i.imgur.com/999999999.png) Division 1-6 11 Division of General, Restorative, Neurological Devices 5
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%